Aeolus Pharmaceuticals, Inc.  

(Public, OTCMKTS:AOLS)   Watch this stock  
Find more results for OTC:AOLS
0.170
0.000 (-0.06%)
May 27 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.16 - 0.17
52 week 0.15 - 0.40
Open 0.16
Vol / Avg. 12,620.00/50,810.00
Mkt cap 25.75M
P/E     -
Div/yield     -
EPS -0.04
Shares 151.56M
Beta 0.70
Inst. own 74%
Aug 15, 2016
Q3 2016 Aeolus Pharmaceuticals Inc Earnings Release (Estimated) Add to calendar
May 16, 2016
Q2 2016 Aeolus Pharmaceuticals Inc Earnings Release
  

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -111.33% -84.47%
Operating margin -111.33% -84.41%
EBITD margin - -84.41%
Return on average assets -39.82% -98.11%
Return on average equity -191.29% -720.00%
Employees 4 -
CDP Score - -

Address

26361 Crown Valley Pkwy Ste 150
MISSION VIEJO, CA 92691-7324
United States - Map
+1-949-4819825 (Phone)
+1-919-5588686 (Fax)

Website links

Description

Aeolus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is developing a platform of compounds with anti-fibrotic, anti-inflammatory, anti-infective and anti-oxidant activity. The Company develops a platform of compounds for use in biodefense, fibrosis, oncology, infectious disease and diseases of the central nervous system. The platform consists of approximately 180 compounds. The Company's lead compound, AEOL 10150 (10150), is developed for the treatment of lung fibrosis, including idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases. The Company is also developing 10150 for use in combination with radiation therapy for cancer as a treatment to reduce side effects caused by radiation toxicity and improve local tumor control. 10150 is also being developed as a medical counter measures (MCM) for exposure to chemical vesicants, such as chlorine gas, sulfur mustard gas and phosgene gas, and nerve agents, such as sarin gas and soman gas.

Officers and directors

David C. Cavalier Chairman of the Board, Interim Chief Financial Officer
Age: 45
John L. McManus President, Chief Executive Officer
Age: 50
John M. Clerici Independent Director
Age: 44
John M. Farah Jr., Ph.D. Independent Director
Age: 62
Mitchell D. Kaye J.D. Independent Director
Age: 46
Amit Kumar Ph.D. Independent Director
Age: 51
Chris A. Rallis Independent Director
Age: 61